Amphastar Pharmaceuticals Inc 2026年季度报告

FORM 10-Q ⌧QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2026or ◻TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period fromtoCommission file number 001-36509 AMPHASTAR PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section13or15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.Yes⌧No◻ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files).Yes⌧No◻ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Largeacceleratedfiler⌧ Non-accelerated filer◻ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.◻ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes◻No⌧ Securities registered pursuant to Section 12(b) of the Act: The number of shares outstanding of the registrant’s only class of common stock as of July 31, 2026 was 42,537,944. AMPHASTAR PHARMACEUTICALS, INC.TABLE OF CONTENTSFORM 10-Q FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2026 Special Note About Forward-Looking Statements Part I. FINANCIAL INFORMATION PAGE Item1. Financial Statements (unaudited):Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31,20251Condensed Consolidated Statements of Operations for the Three and Six MonthsEnded June 30, 2026 and 20252Condensed Consolidated Statements of Comprehensive Income for the Three andSix Months Ended June 30, 2026 and 20253Condensed Consolidated Statements of Stockholders’ Equity for the Three and SixMonths Ended June 30, 2026 and 20254Condensed Consolidated Statements of Cash Flows for the Six Months Ended June30, 2026 and 20255Notes to Condensed Consolidated Financial Statements6Item 2. Management’s Discussion and Analysis of Financial Condition and Results ofOperations31Item 3. Quantitative and Qualitative Disclosure about Market Risk40Item 4. Controls and Procedures40Part II. OTHER INFORMATIONItem 1. Legal Proceedings41Item 1A. Risk Factors41Item 2. Unregistered Sales of Equity Securities and Use of Proceeds43Item 3. Defaults Upon Senior Securities43Item 4. Mine Safety Disclosures43Item 5. Other Information43Item 6. Exhibits44Signatures45 SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or Quarterly Report, contains “forward-looking statements” that involvesubstantial risks and uncertainties. In some cases, you can identify forward-looking statements by the following words:“may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,”“predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparableterminology, although not all forward-looking statements contain these identifying words. Forward-looking statementsrelate to future events or future financial performance or condition and involve known and unknown risks,uncertainties and other factors that could cause actual results, levels of activity, performance or achievement to differmaterially from those expressed or implied by the forward-looking statements. These forward-looking statementsinclude, but are not limited to, statements about: ●our expectations regarding the sales and marketing of our products;●our expectations regarding our manufacturing and production and the integrity of our supply chain for ourproducts, including the risks associated with our single source suppliers;●our business and operations in general, including: adverse impacts of global conflicts and challengingmacroeconomic conditions and market uncertainty on our business, financial condition, operations, cashflows and liquidity;●our ability to attract, hire, and retain highly skilled personnel;●interruptions to our manufacturing and production as a result of natural catastrophic events or other causesbeyond our control such as power disruptions, pandemics, wars, terrorist attacks or ot